Results 161 to 170 of about 108,588 (261)

Temporal dynamics of immune effector cell‐associated haematotoxicity: Linking early and late cytopenias after chimeric antigen receptor T cells

British Journal of Haematology, EarlyView.
Malvina Bichon, Roch Houot, Mana Alshehri, Guillaume Manson, Faustine Lhomme, Samuel Vic   +5 more
wiley   +1 more source

Tumor‐Derived Exosomal piR‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer

Cancer Science, EarlyView.
Breast cancer–derived exosomal piR‐hsa‐28212 promotes lymphangiogenesis and lymph node metastasis by activating VEGFC/VEGFR3 signaling. It stabilizes TBX1 mRNA in lymphatic endothelial cells and METTL3 protein in tumor cells, enhancing VEGFR3 expression and VEGFC secretion.
Yafen Wang, Tianli Zhang, Xue Kong, Yao Tong, Yanru Li, Xiangjun Dong, Chuanxin Wang, Juan Li   +7 more
wiley   +1 more source

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma. [PDF]

Curr Oncol
Mozessohn L, Villeneuve PJA, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung MC, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW.   +17 more
europepmc   +1 more source

Diffuse large B-cell lymphoma in the elderly [PDF]

Blood, 2017
openaire   +2 more sources

Mechanisms of resistance to macrophage checkpoint inhibitors in B‐cell non‐Hodgkin lymphoma

British Journal of Haematology, EarlyView.
Zachary Hunzeker, Francisco Javier de la Rosa, Andrey Tyshevich, Darya Shavronskaya, Julia Alesse, Noel English, Lizzie Sheehan, Nikita Syzrantsev, Alexander Nesmelov, Hans‐Guido Wendel, Paolo Strati   +10 more
wiley   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

Zhang B, Xie Y, Shen M, et al. Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma. Blood Adv. 2025;9(13):3249-3262. [PDF]

Blood Adv
europepmc   +1 more source

Predictive model for survival outcomes in rare primary glandular diffuse large B-cell lymphoma. [PDF]

Medicine (Baltimore)
Lu J, Liang C, Zhu X.
europepmc   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

Atypical Ulcerated Cutaneous Presentation of Diffuse Large B-Cell Lymphoma: A Case Report. [PDF]

Cureus
Nogueira P, Rodrigues IV, Reboredo P, Pylyp N, Mogildea M.   +4 more
europepmc   +1 more source